460 related articles for article (PubMed ID: 34639141)
1. Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy.
Gavali S; Liu J; Li X; Paolino M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639141
[TBL] [Abstract][Full Text] [Related]
2. Targeting ubiquitin signaling for cancer immunotherapy.
Zhou X; Sun SC
Signal Transduct Target Ther; 2021 Jan; 6(1):16. PubMed ID: 33436547
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Cancer Immune Checkpoint: Mono- and Poly-Ubiquitination: Tags for Fate.
Yao H; Xu J
Adv Exp Med Biol; 2020; 1248():295-324. PubMed ID: 32185716
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.
Fujita Y; Tinoco R; Li Y; Senft D; Ronai ZA
Trends Mol Med; 2019 May; 25(5):428-443. PubMed ID: 30898473
[TBL] [Abstract][Full Text] [Related]
5. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
6. Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges.
Ye P; Chi X; Cha JH; Luo S; Yang G; Yan X; Yang WH
Cells; 2021 Nov; 10(12):. PubMed ID: 34943817
[TBL] [Abstract][Full Text] [Related]
7. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapies and Combination Strategies for Immuno-Oncology.
Barbari C; Fontaine T; Parajuli P; Lamichhane N; Jakubski S; Lamichhane P; Deshmukh RR
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679922
[TBL] [Abstract][Full Text] [Related]
9. Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies.
Chen M; Hu S; Li Y; Jiang TT; Jin H; Feng L
Signal Transduct Target Ther; 2020 Nov; 5(1):270. PubMed ID: 33214545
[TBL] [Abstract][Full Text] [Related]
10. Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways.
Liu J; Cheng Y; Zheng M; Yuan B; Wang Z; Li X; Yin J; Ye M; Song Y
Signal Transduct Target Ther; 2021 Jan; 6(1):28. PubMed ID: 33479196
[TBL] [Abstract][Full Text] [Related]
11. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
Chiang EY; Mellman I
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379739
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
13. Targeting T cell activation in immuno-oncology.
Saibil SD; Ohashi PS
Curr Oncol; 2020 Apr; 27(Suppl 2):S98-S105. PubMed ID: 32368179
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.
Liu X; Bao X; Hu M; Chang H; Jiao M; Cheng J; Xie L; Huang Q; Li F; Li CY
Nature; 2020 Dec; 588(7839):693-698. PubMed ID: 33177715
[TBL] [Abstract][Full Text] [Related]
15. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
16. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
17. NK Cell-Based Immune Checkpoint Inhibition.
Khan M; Arooj S; Wang H
Front Immunol; 2020; 11():167. PubMed ID: 32117298
[TBL] [Abstract][Full Text] [Related]
18. Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.
Nakajima H; Nakatsura T
Immunol Med; 2021 Mar; 44(1):10-15. PubMed ID: 32643578
[TBL] [Abstract][Full Text] [Related]
19. Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ.
Chandrasekaran S; Funk CR; Kleber T; Paulos CM; Shanmugam M; Waller EK
Front Immunol; 2021; 12():718621. PubMed ID: 34512641
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
